Asunto(s)
Antiinflamatorios/uso terapéutico , Antivirales/uso terapéutico , Betacoronavirus/fisiología , Bosentán/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Antagonistas de los Receptores de la Endotelina A/uso terapéutico , Neumonía Viral/tratamiento farmacológico , Valsartán/uso terapéutico , Antiinflamatorios/farmacología , Antivirales/farmacología , Bosentán/farmacología , COVID-19 , Células Cultivadas , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/virología , Citocinas/metabolismo , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Antagonistas de los Receptores de la Endotelina A/farmacología , Humanos , Modelos Biológicos , Pandemias/prevención & control , Neumonía Viral/prevención & control , Neumonía Viral/virología , ARN Viral/análisis , Receptor de Endotelina A/fisiología , SARS-CoV-2 , Valsartán/farmacología , Virosis/tratamiento farmacológico , Tratamiento Farmacológico de COVID-19RESUMEN
Morphea is an inflammatory, fibrosing skin disorder. When it occurs in childhood, it is also known as localized juvenile scleroderma. It is more common in girls and typically appears around the age of 5 to 7 years. According to a recent classification system, morphea is divided into 5 types: circumscribed (plaque), linear, generalized, pansclerotic, and mixed. Approximately 40% of patients present extracutaneous manifestations. Childhood morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentán, and topical imiquimod 5%. A variety of measuring tools are used to monitor response to treatment. Few prognostic studies have been conducted, but findings to date suggest that the disease tends to run a chronic or intermittent-recurrent course and frequently causes sequelae.